Poseida follows the lead of PACT Pharma and the Fred Hutchinson Cancer Research Center, both of which have already partnered with Cellares to advance a closed, automated, and scalable cell therapy manufacturing system.

Under the partnership, Poseida will provide insight into autologous and allogeneic CAR T workflows, as well as programs that include T-cell receptor engineering, genetically modified NK cells, and other cell therapy manufacturing workflows.

The EAPP was established in 2020 to provide participants with visibility and early access to Cellares' Cell Shuttle, a cell therapy manufacturing platform enabling closed, automated, and scalable production of cell therapies.

Cellares raises $82M to make scalable 'factory-in-a-box'
Life sciences technology company Cellares has raised $82 million in financing to accelerate the development of the scalable factory-in-a-box Cell...

Poseida CAR T clinical trial hold lifted
The U.S. Food and Drug Administration has lifted a clinical trial hold on Poseida Therapeutics' phase I study of P-PSMA-101, an autologous chimeric antigen...

Poseida, TScan partner on allogenic TCR therapies for COVID-19
Poseida Therapeutics and TScan Therapeutics are joining forces to develop T-cell receptor (TCR) therapies for the treatment of COVID-19.